FCRL5 and neoplasm: Since FcRH5 expression occurs independently of BCMA, FcRH5-directed therapies may be beneficial for targeting BCMA low or negative tumor cells and re-invigorating BCMA CAR T cells against residual BCMA-positive tumor cells.